Gil Verschelden
A5016277444- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Trace Elements in Health
- Synthesis and biological activity
- Melanoma and MAPK Pathways
- Infectious Encephalopathies and Encephalitis
- Neonatal Respiratory Health Research
- Congenital Diaphragmatic Hernia Studies
- Antibiotic Use and Resistance
- Antibiotics Pharmacokinetics and Efficacy
- Quinazolinone synthesis and applications
- Vitamin C and Antioxidants Research
- Histiocytic Disorders and Treatments
- Antibiotic Resistance in Bacteria
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Viral Infections and Immunology Research
- Blood disorders and treatments
- COVID-19 and healthcare impacts
- Eosinophilic Disorders and Syndromes
- Nutrition, Genetics, and Disease
- Celiac Disease Research and Management
- Influenza Virus Research Studies
- Muscle and Compartmental Disorders
- Diagnosis and treatment of tuberculosis
Universitair Ziekenhuis Brussel
2015-2023
Vrije Universiteit Brussel
2016-2023
Université Libre de Bruxelles
2020-2022
Erasmus Hospital
2022
Approximately half of BRAF-mutated Non-small cell lung cancers (NSCLCs) harbor a non-V600 BRAF mutation, accounting for ∼40,000 annual deaths worldwide. Recent studies have revealed the benefits combined targeted therapy with RAF-inhibitor (Dabrafenib) and MEK-inhibitor (Trametinib) in treating V600 mutant cancers, including NSCLC. In contrast, sensitivity mutations to these inhibitors is not documented. Non-V600 can either increase or impair kinase activity. However, impaired kinases still...
SummaryBackgroundInfections with SARS-CoV-2 continue to cause significant morbidity and mortality. Interleukin (IL)-1 IL-6 blockade have been proposed as therapeutic strategies in COVID-19, but study outcomes conflicting. We sought whether of the or IL-1 pathway shortened time clinical improvement patients hypoxic respiratory failure, signs systemic cytokine release syndrome.MethodsWe did a prospective, multicentre, open-label, randomised, controlled trial, hospitalised hypoxia, syndrome...
Abstract Background We aimed to evaluate the cardiac adverse events (AEs) in hospitalized patients with coronavirus disease 2019 (COVID-19) who received remdesivir plus standard of care (SoC) compared SoC alone (control), as an association was noted some cohort studies and disproportionality analyses safety databases. Methods This post hoc analysis is based on data from multicenter, randomized, open-label, controlled DisCoVeRy trial COVID-19. Any first AE that occurred between randomization...
Introduction Antimicrobial resistance is a growing problem that necessitates the development of new therapeutic options. Cefiderocol and aztreonam (AT) are often last active β-lactams for treating metallo-β-lactamases (MBL)-producing Gram-negative bacilli. In these difficult-to-treat bacterial strains, AT frequently attributed to co-occurrence other mechanisms. case β-lactamases they can be inhibited by avibactam. present study, we evaluated use double-disc synergy test (DDST) as screening...
Despite the low rates of bacterial co-/superinfections in COVID-19 patients, antimicrobial drug use has been liberal since start pandemic. Due to specificity markers co-/superinfection setting, overdiagnosis and overprescription have become widespread. A quantitative qualitative evaluation urinary tract infection (UTI) diagnoses prescriptions for UTI was performed patients admitted ward a university hospital between 17 March 2 November 2020. team infectious disease specialists an...
The incidence of tuberculosis lymphadenopathy (TBLA) is increasing, and diagnostic procedures lack sensitivity are often highly invasive. TBLA may be asymptomatic, differential diagnosis with other adenopathies (ADPs) difficult. We evaluated a blood-cell interferon-γ release assay (IGRA) two different stage-specific mycobacterial antigens for the ADP suspected origin. Twenty-one patients were included divided into three groups: (1) cervical/axillar (n = 8), (2) mediastinal 10), (3)...
Although many different treatment regimens have been proposed, only a few are based on evidence from randomized controlled trials.Only vemurafenib was approved by the Food and Drug Administration in November 2017 for patients with BRAF V600E -mutant ECD.The proposed literature include corticoids, interferon alfa, anakinra, infliximab, tocilizumab, cyclophosphamide, anthracyclines, vinca alkaloids, vemurafenib, dabrafenib, combination therapy of dabrafenib trametinib.A large case series has...
The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic for which there is no established treatment available yet, has caused more than 68,000 deaths so far. Following the SARS-CoV outbreak in 2003, an Italian group described a hypothesis about efficacy of two old drugs: Chloroquine (CQ) and Hydroxychloroquine (HCQ), against its future emergents. Later, this was shown to be relevant in-vitro. Due high genetic similarity SARS-CoV-2 SARS-CoV, introduced by Savarino et...
Abstract Background The antiviral efficacy of remdesivir is still controversial. We aimed at evaluating its clinical effectiveness in hospitalised patients with COVID-19, indication oxygen and/or ventilator support. Following prior publication preliminary results, here we present the final results after completion data monitoring. Methods In this European multicentre, open-label, parallel-group, randomised, controlled trial (DisCoVeRy, NCT04315948 ; EudraCT2020-000936-23), participants were...
Background: The antiviral efficacy of remdesivir is still controversial. We aimed at evaluating its clinical effectiveness in patients with COVID-19 requiring oxygen and/or ventilator support.Methods: In this European multicentre, open-label, parallel-group, randomised, controlled trial adults hospitalised (DisCoVeRy, NCT04315948; EudraCT2020-000936-23), participants were randomly allocated to receive usual standard care alone or combination intravenous (200 mg on day 1, then 100 once-daily...
11091 Background: The most common BRAF mutations in non-small cell lung cancer (NSCLC) are non-V600 contrast to melanoma. pathway inhibitors have not been systematically investigated vitro and the clinic. We tested effect of two clinically available (Trametinib Dabrafenib) on a subset identified cohort cancers enriched for adenocarcinoma patients with no or limited smoking history. Methods: NSCLC tumor samples (FFPE) were presence EGFR, KRAS, NRAS, HRAS by DGGE NGS-based methods. generated...
Abstract Deficiency of the element zinc is associated with cytokine releasing syndrome (CRS) and related acute respiratory distress as well impaired antiviral response. Similar complications associate severe SARS-CoV-2. We conducted a prospective, single-center, observational study in tertiary university hospital (CUB-Hopital Erasme, Brussels) to address status, association between plasma concentration, development CRS, clinical outcomes PCR-confirmed hospitalized COVID-19 patients. One...
Background: The antiviral efficacy of remdesivir is still controversial. We aimed at evaluating its clinical effectiveness in patients with COVID-19 requiring oxygen and/or ventilator support. Methods: In this European multicentre, open-label, parallel-group, randomised, controlled trial adults hospitalised (DisCoVeRy, NCT04315948; EudraCT2020-000936-23), participants were randomly allocated to receive usual standard care alone or combination intravenous (200 mg on day 1, then 100 once-daily...